By complexing RES with cyclodextrin (CD) and encapsulating it in poly lactic glycolic acid (PLGA) NPs, functionalized with transferrin ligands, the researchers aimed to improve RES targeting to NSCLC cells via transferrin receptor (TfR)-mediated endocytosis, thereby enhancing therapeutic outcomes and reducing off-target toxicity. The gene discussed is TFRC; the disease is non-small cell lung carcinoma.